Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMIXNASDAQ:IRIXNASDAQ:VVOSNASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMIXAutonomix Medical$1.43-12.8%$1.81$1.31▼$42.40$3.98M-3.47331,464 shs4.09 million shsIRIXIRIDEX$1.00+2.0%$1.04$0.78▼$2.48$16.79M0.6948,859 shs34,074 shsVVOSVivos Therapeutics$2.25-3.8%$2.50$1.97▼$6.28$13.25M7.02154,766 shs45,301 shsXAIRBeyond Air$0.18-2.7%$0.21$0.16▼$1.49$15.81M0.251.24 million shs1.11 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMIXAutonomix Medical+2.50%-3.53%-18.00%-34.40%-95.79%IRIXIRIDEX+2.10%+3.40%-14.77%-22.82%-59.16%VVOSVivos Therapeutics-0.85%+2.18%-10.34%-37.10%+7.83%XAIRBeyond Air+0.11%-1.05%-9.62%-28.71%-84.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMIXAutonomix Medical3.2415 of 5 stars3.54.00.00.02.61.71.3IRIXIRIDEX0.6727 of 5 stars0.03.00.00.02.61.70.0VVOSVivos Therapeutics2.3469 of 5 stars3.35.00.00.02.00.00.6XAIRBeyond Air4.2943 of 5 stars3.53.00.03.52.22.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMIXAutonomix Medical 3.00Buy$16.501,053.85% UpsideIRIXIRIDEX 0.00N/AN/AN/AVVOSVivos Therapeutics 2.50Moderate Buy$4.82114.07% UpsideXAIRBeyond Air 3.00Buy$1.50719.67% UpsideCurrent Analyst Ratings BreakdownLatest AMIX, XAIR, IRIX, and VVOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025VVOSVivos TherapeuticsIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.255/20/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/29/2025AMIXAutonomix MedicalMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.004/15/2025VVOSVivos TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.60 ➝ $6.204/1/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMIXAutonomix MedicalN/AN/AN/AN/A$8.12 per shareN/AIRIXIRIDEX$48.80M0.34N/AN/A$0.59 per share1.69VVOSVivos Therapeutics$14.63M0.91N/AN/A$0.22 per share10.23XAIRBeyond Air$3.02M5.23N/AN/A$0.27 per share0.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMIXAutonomix Medical-$15.43M-$7.47N/AN/AN/AN/A-212.48%-161.13%N/AIRIXIRIDEX-$9.57M-$0.43N/A∞N/A-22.79%-192.95%-33.97%8/6/2025 (Estimated)VVOSVivos Therapeutics-$13.58M-$1.73N/AN/AN/A-86.19%-335.04%-93.58%8/13/2025 (Estimated)XAIRBeyond Air-$60.24M-$1.06N/AN/AN/A-1,730.00%-226.01%-109.75%6/17/2025 (Estimated)Latest AMIX, XAIR, IRIX, and VVOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/17/2025Q4 2025XAIRBeyond Air-$0.14N/AN/AN/A$1.39 millionN/A5/29/2025Q4 2025AMIXAutonomix MedicalN/A-$0.74N/A-$0.74N/AN/A5/15/2025Q1 2025VVOSVivos Therapeutics-$0.44-$0.45-$0.01-$0.45$3.63 million$3.70 million5/13/2025Q1 2025IRIXIRIDEX-$0.10-$0.10N/A-$0.10$12.10 million$11.90 million3/27/2025Q4 2024IRIXIRIDEX-$0.05-$0.05N/A-$0.05$12.80 million$12.70 million3/27/2025Q4 2024VVOSVivos Therapeutics-$0.43-$0.28+$0.15-$0.28$3.89 million$3.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMIXAutonomix MedicalN/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMIXAutonomix MedicalN/A5.315.31IRIXIRIDEX0.551.540.85VVOSVivos TherapeuticsN/A1.441.44XAIRBeyond AirN/A3.563.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMIXAutonomix Medical10.78%IRIXIRIDEX20.10%VVOSVivos Therapeutics26.35%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipAMIXAutonomix Medical32.40%IRIXIRIDEX7.30%VVOSVivos Therapeutics3.00%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMIXAutonomix Medical12.78 million1.67 millionN/AIRIXIRIDEX12016.79 million15.42 millionOptionableVVOSVivos Therapeutics1605.89 million5.71 millionOptionableXAIRBeyond Air7086.37 million54.97 millionOptionableAMIX, XAIR, IRIX, and VVOS HeadlinesRecent News About These CompaniesBeyond Oil Issues Clarification Regarding Previous German-Language Media ActivitiesJune 3 at 5:08 PM | globenewswire.comBeyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and WebcastMay 20, 2025 | globenewswire.comBeyond Air granted U.S. patent for gaseous nitric oxide deliveryApril 25, 2025 | markets.businessinsider.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Gets Patent for Lung Infection TreatmentApril 25, 2025 | marketwatch.comBeyond Air granted U.S. patent for treatment of NTM infections using gaseous Nitric OxideApril 25, 2025 | msn.comBeyond Air, Inc. Secures U.S. Patent for Novel Nitric Oxide Delivery Method in Treating NTM Lung InfectionsApril 24, 2025 | quiverquant.comBeyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to AutismApril 23, 2025 | finanznachrichten.deNeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to AutismApril 21, 2025 | globenewswire.comNeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory BoardApril 15, 2025 | globenewswire.comBeyond Air subsidiary granted orphan designation for Phelan-McDermid treatmentApril 15, 2025 | markets.businessinsider.comJonesTrading Sticks to Their Buy Rating for Beyond Air (XAIR)April 15, 2025 | markets.businessinsider.comBeyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at HomeApril 9, 2025 | globenewswire.comBeyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at HomeApril 9, 2025 | globenewswire.comBeyond Air subsidiary NeuroNOS announces publication of researchApril 2, 2025 | markets.businessinsider.comBeyond Air announces VUMC as first luminary siteApril 1, 2025 | markets.businessinsider.comBeyond Air Announces Vanderbilt University Medical Center as First Luminary SiteMarch 31, 2025 | globenewswire.comNeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism TherapyMarch 24, 2025 | globenewswire.comBeyond Air (XAIR): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMIX, XAIR, IRIX, and VVOS Company DescriptionsAutonomix Medical NASDAQ:AMIX$1.43 -0.21 (-12.80%) As of 02:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.IRIDEX NASDAQ:IRIX$1.00 +0.02 (+2.02%) As of 02:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.Vivos Therapeutics NASDAQ:VVOS$2.25 -0.09 (-3.85%) As of 02:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.Beyond Air NASDAQ:XAIR$0.18 -0.01 (-2.66%) As of 02:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
